Page 49 - Colitis Foundation News Today

/PRNewswire/ -- Athos Therapeutics, Inc., a late preclinical stage biotechnology company pioneering the development of first-in-class precision therapeutics...

/PRNewswire/ -- Athos Therapeutics, Inc., a late preclinical stage biotechnology company pioneering the development of first-in-class precision therapeutics...

The La Jolla Light presents this continuing series of online activities to undertake on your computer or tablet, as well as local in-person events. • The La Jolla Community Center presents "The Promises and Dangers of Early Multi-Cancer Screening Tests: Are We Ready?”

Biosimilar drugs are cheaper and supposed to be just as effective as their biologic counterparts.

There’s no good time during Phoenix’s hot summer to train for a cycling event.

NORTH CHICAGO, Ill., Oct. 2, 2021 /PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab  in Crohns disease, upadacitinib in ulcerative colitis and... | October 3, 2021

AbbVie today announced new data on the investigational use of risankizumab  in Crohn's disease, upadacitinib in ulcerative colitis and HUMIRA ® in inflammatory bowel disease will be presented as live presentations and e-Posters at the United European Gastroenterology Week Virtual 2021, to be held October 3-5 . AbbVie is presenting a total of 13 abstracts, across a broad range of studies in IBD, including two ...

/PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI®) in Crohns disease, upadacitinib (RINVOQ®) in ulcerative...

/PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI®) in Crohns disease, upadacitinib (RINVOQ®) in ulcerative...

Studies show that individuals who consume processed foods are more likely to develop IBD. Here are foods to avoid and what to eat if you have IBD or IBS.